Advertisement

MMW - Fortschritte der Medizin

, Volume 161, Issue 7, pp 48–52 | Cite as

Konsequente Abklärung erhöhter Leberwerte

Leberzirrhose und Komplikationen rechtzeitig erkennen

  • Manfred GrossEmail author
FORTBILDUNG . ÜBERSICHT
  • 36 Downloads

In der Praxis müssen Sie mit einer steigenden Zahl von Leberzirrhose-Fällen rechnen, nicht nur aufgrund von Alkoholabusus und Virushepatitiden, sondern auch wegen der Zunahme von Adipositas und metabolischem Syndrom. Wie erkennen Sie Betroffene frühzeitig?

Hepatic cirrhosis: early diagnosis and prevention of complications

Keywords

Hepatic cirrhosis acites variceal bleeding hepatic encephalopathy 

Literatur

  1. 1.
    Niederau C, Epidemiologie der Leberzirrhose. Hepatitis&more 1/2011-1Google Scholar
  2. 2.
    Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014 May 17;383(9930):1749–61.CrossRefGoogle Scholar
  3. 3.
    Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015;149(2):367–78CrossRefGoogle Scholar
  4. 4.
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019 Jan;70(1):172–193. doi:  https://doi.org/10.1016/j.jhep.2018.06.024.CrossRefGoogle Scholar
  5. 5.
    Runyon BA et al., Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013 57(4):1651–3.CrossRefGoogle Scholar
  6. 6.
    Gerbes AL, Gülberg V, Sauerbruch T, Wiest R, Appenrodt B, Bahr MJ, Dollinger MM, Rössle M, Schepke M. German S 3-guideline „ascites, spontaneous bacterial peritonitis, hepatorenal syndrome“. Z Gastroenterol. 2011 Jun;49(6):749–79.CrossRefGoogle Scholar
  7. 7.
    Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715–35.CrossRefGoogle Scholar
  8. 8.
    Prakash RK, Kanna S, Mullen KD. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis. Clin Ther. 2013 Sep;35(9):1458–73.CrossRefGoogle Scholar
  9. 9.
    Varakanahalli S, Sharma BC, Srivastava S, Sachdeva S, Dahale AS. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. Eur J Gastroenterol Hepatol 2018;30(8):951–958CrossRefGoogle Scholar
  10. 10.
    Bass NM1, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.CrossRefGoogle Scholar
  11. 11.
    Kalambokis GN et al., Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012 Jul;10(7):815–8CrossRefGoogle Scholar
  12. 12.
    Kimer N et al., Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014 Jul;40(2):123–32CrossRefGoogle Scholar
  13. 13.
    Garcia-Tsao G et al., Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310–335CrossRefGoogle Scholar
  14. 14.
    Sinagra E et al., Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014 Mar;39(6):557–68CrossRefGoogle Scholar
  15. 15.
    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik und Therapie des hepatozellularen Karzinoms, Langversion 1.0, 2013. AWMF Registrierungsnummer: 032-053OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html
  16. 16.
    Ge PS, Runyon BA; When should the β-blocker window in cirrhosis close? Gastroenterology. 2014 Jun;146(7):1597–9CrossRefGoogle Scholar
  17. 17.
    Delco F et al., Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529–45.CrossRefGoogle Scholar
  18. 18.
    Weersink RA et al., Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018 Aug;84(8):1806–1820CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Internistisches Klinikum München SüdMünchenDeutschland

Personalised recommendations